Kadmon competitors

Kadmon's competitors include Biogen, MyoKardia, Athersys and Neurocrine Biosciences
Add company...
Kadmon
Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Neurocrine Biosciences
Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
Founding Date
Founding Date
2010
Founding Date
1978
Founding Date
2012
Founding Date
1995
Founding Date
1992
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
San Diego, US HQ
Employees
Employees
10010% decrease
Employees
7,3001% decrease
Employees
1024% increase
Employees
60
Employees
400
Valuation ($)
Valuation ($)
295.5 m
Valuation ($)
64.5 b
Valuation ($)
1.8 b
Valuation ($)
321.4 m
Valuation ($)
9 b
Facebook likes
Facebook likes
N/A
Facebook likes
3.1 k
Facebook likes
N/A
Facebook likes
475
Facebook likes
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
19.4 k
Twitter followers
387
Twitter followers
953
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$12.3m (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
$15m (FY, 2016)
Net income
Net income
($79.8m) (FY, 2017)
Net income
$3.7b (FY, 2016)
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($141.1m) (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 21.3m
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 10m
For sources of this data, please see the company profileDownload Excel

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,300↓ 1% decrease

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Neurocrine Biosciences
HQ
San Diego, US
Employees
400

Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.

View company